HIGHLIGHTS
- who: Pau Montesinos from the Department of Hematology, Hospital Universitario y Torre A, u00ba planta, Valencia, Spain Medical College of Georgia, Augusta University, Augusta have published the paper: A phase IV study evaluating QT interval, pharmacokinetics, and safety following fractionated dosing of gemtuzumab ozogamicin in patients with relapsed/refractory CD33-positive acute myeloid leukemia, in the Journal: (JOURNAL)
- what: This study showed that fractionated dosing of GO (3 mg/m2 on Days 1, 4, and 7) is not predicted to pose a clinically significant safety risk for QT interval prolongation in patients with R/R . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.